Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-934-5 | CAS number: -
The acute dermal and oral toxicity of EUF was above 2000 mg/kg bw.
Table for Acute Oral Toxicity of TPI 1618
Dose [mg/kg bw]
Number of dead /number of investigated
Time of death (range)
Clinical signs:piloerection, hunched posture,
> 2000 mg/kg bw
Study was performed according to OECD guideline 420 (fixed dose procedure). One dose level of 2000 mg/kg bw. was used and applied orally as single administration to 4 females rats. All survivors were subjected to a 14 days post-treatment observation period. All rats were observed for clinical signs, body weight development. Macroscopic findings were recorded in all animals.
No animal died. Clinical signs observed at the 2000 mg/kg dose level were piloerection and hunched posture p to 6 hours post dosing. Body weight development was within normal ranges. No macroscopic organ findings were observed at necropsy.
Table for acute dermal toxicity: clinical signs and pathology
Dose (mg/kg bw.)
males 0/5,females 0/5
Clinical signs: Piloerection up to and including Day 1 p.a. in all animals
Pathologyno specific findings
>2000 mg/kg bw.
The study was performed according to OECD guideline 402 and designed as a limit-test using a single dose of 2000 mg/kg bw in rats. No pre-terminal deaths were observed in any of the rats after dermal application of 2000 mg/kg bw. Clinical signs were limited to piloerection up to and including Day 1 of dosing. Yellowish staining of the skin was induced by the test item. The LD50for male and female rats after dermal exposure was greater than 2000 mg/kg bw. Thus no classification is required.
Acute oral and dermal toxicity was investigated in studies according to current guidelines. The acute oral toxicity of EUF was above 2000 mg/kg bw in a limit test. Clinical signs observed in rats after oral application were hunched posture and piloerection. Pathology revealed no treatment-related effects.
An acute inhalation toxicity study with EUF has not been performed.
Though the existing and most recently performed acute dermal irritation study with EUF did not indicate EUF to be an irritant compound, however, irritation can nevertheless be expected if the test item is allowed to hydrolyse. The maximum releasable formaldehyde portion of 49% from EUF is expected to cause burns. Therefore, testing inhalation route is not regarded as scientifcally justified.
Acute oral toxicity
Based on the most recent data with LD50 values of > 2000 mg/kg bw, there is no need for a classification according to the CLP regulations of EC Directive 1272/2008 and GHS.
Acute inhalation toxicity
Classification not possible. No study performed.
Acute dermal toxicity
Based on the data with an acute dermal toxicity of >2000 mg/kg bw, there is no need for a classification according to the CLP regulations of EC Directive 1272/2008 and GHS.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again